Compare Heron Therapeutics Inc (HRTX) vs Norfolk Southern Corporation (NSC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Heron Therapeutics Inc vs Norfolk Southern Corporation — how do they compare? Heron Therapeutics Inc trades at $0.36 (market cap $68.01M), while Norfolk Southern Corporation trades at $317.24 (market cap $71.20B). The key difference: Norfolk Southern Corporation is far larger — about 1046.9× Heron Therapeutics Inc's market cap, and Norfolk Southern Corporation pays a 1.7% dividend while Heron Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Heron Therapeutics Inc for 35 Days and Norfolk Southern Corporation for 33 Days on average.
| HRTX | NSC | |
|---|---|---|
Market Cap | $68.01M | $71.20B |
Volume | 1,891,941 | 555,248 |
Sector | Health | Industrials |
52-Week High | $1.49 | $352.98 |
52-Week Low | $0.27 | $278.19 |
Typical Hold Time | 35 Days | 33 Days |
Enterprise Value | $174.75M | $86.75B |
Dividend Yield | — | 1.7% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Heron Therapeutics (HRTX) is trading at $0.39, up 17.58% today, with a bullish technical outlook from moving averages but mixed signals from oscillators. The company maintains strong gross margins of 70.07% but continues to report net losses, with Q2 2026 missing both EPS and revenue expectations. Analyst sentiment remains overwhelmingly positive with 89% buy ratings despite recent earnings disappointments and negative profitability metrics.
While analyst consensus is strongly bullish, HRTX faces significant fundamental challenges including consistent net losses, negative ROE of -78.72%, and cash flow concerns. The stock's current momentum appears driven by technical factors rather than improving fundamentals, creating a high-risk investment profile that requires careful monitoring of upcoming Q3 earnings and revenue stabilization efforts.
Norfolk Southern (NSC) trades at $313.20, down 0.98% on the day, with a bearish technical outlook despite strong fundamentals. The company has consistently beaten earnings expectations in recent quarters, with Q2 2026 EPS of $3.52 exceeding the $3.32 forecast. Key developments include the proposed merger with Union Pacific, which is progressing through regulatory review and expected to close by late 2027. Financial metrics show solid profitability with 21.02% net income margin and 16.97% ROE, though cash flow trends indicate negative net cash flow in both 2025 and 2026.
The investment case balances strong operational performance against merger execution risks and technical weakness. With 44% analyst buy ratings and a $361.86 consensus price target suggesting 15% upside, the stock offers value if merger benefits materialize. However, regulatory hurdles, fuel cost pressures, and bearish technical signals warrant caution for near-term investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →About Norfolk Southern Corporation
Norfolk Southern Corporation is a major North American railroad company operating one of the largest freight rail networks in the eastern United States. The company transports a diverse range of commodities, including coal, intermodal containers, and various industrial products. NSC is a critical link in the nation's supply chain, providing efficient, long-haul transportation services to and from ports and industrial centers.
Read more on NSC →
